LifeStance Health Group (LFST) Financials

$5.83 -0.01 (-0.17%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$5.75 -0.08 (-1.44%)

As of 07:25 AM Eastern

Annual Income Statements for LifeStance Health Group

This table shows LifeStance Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	-57	-186	-216	-344	-59
Consolidated Net Income / (Loss)	-57	-186	-216	-307	5.67
Net Income / (Loss) Continuing Operations	-57	-186	-216	-307	5.67
Total Pre-Tax Income	-58	-207	-233	-333	7.88
Total Operating Income	-32	-189	-210	-286	15
Total Gross Profit	1,251	1,056	860	668	213
Total Revenue	1,251	1,056	860	668	213
Operating Revenue	1,251	1,056	860	668	213
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	1,283	1,245	1,070	954	197
Selling, General & Admin Expense	363	411	378	900	191
Depreciation Expense	71	80	69	54	6.10
Other Operating Expenses / (Income)	849	754	623	-	-
Total Other Income / (Expense), net	-26	-17	-23	-47	-7.37
Interest Expense	27	21	20	39	5.41
Other Income / (Expense), net	0.54	3.77	-2.63	-7.84	-1.96
Income Tax Expense	-0.17	-20	-17	-26	2.21
Weighted Average Basic Shares Outstanding	379.15M	367.46M	355.28M	327.52K	0.00
Weighted Average Diluted Shares Outstanding	379.15M	367.46M	355.28M	327.52K	0.00
Weighted Average Basic & Diluted Shares Outstanding	384.55M	380.69M	376.37M	327.52K	0.00

This table shows LifeStance Health Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	0.71	-7.11	-5.96	-23	-21	-45	-62	-45	-34	-47	-38
Consolidated Net Income / (Loss)	0.71	-7.11	-5.96	-23	-21	-45	-62	-45	-34	-47	-38
Net Income / (Loss) Continuing Operations	0.71	-7.11	-5.96	-23	-21	-45	-62	-45	-34	-47	-38
Total Pre-Tax Income	-1.47	-8.88	-5.38	-23	-21	-38	-78	-52	-38	-54	-42
Total Operating Income	1.60	1.06	0.05	-16	-17	-32	-74	-48	-34	-46	-39
Total Gross Profit	333	325	313	312	300	281	263	260	253	229	218
Total Revenue	333	325	313	312	300	281	263	260	253	229	218
Operating Revenue	333	325	313	312	300	281	263	260	253	229	218
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	331	324	313	328	317	313	337	308	287	275	256
Selling, General & Admin Expense	94	-539	298	310	295	-463	318	288	268	-366	239
Depreciation Expense	14	15	15	19	23	22	20	20	19	19	18
Other Operating Expenses / (Income)	223	-	-	-	-	-	-	-	-	-	-
Total Other Income / (Expense), net	-3.07	-9.94	-5.43	-6.67	-3.96	-6.05	-3.61	-3.61	-4.19	-7.70	-3.37
Interest Expense	3.07	9.40	5.41	5.82	5.90	5.53	5.48	5.12	5.09	5.17	4.19
Other Income / (Expense), net	-0.00	-0.54	-0.02	-0.85	1.94	-0.51	1.87	1.51	0.91	-2.54	0.82
Income Tax Expense	-2.18	-1.76	0.58	0.66	0.36	6.64	-16	-6.54	-4.04	-7.06	-4.35
Weighted Average Basic Shares Outstanding	383.27M	379.15M	380.36M	379.43M	376.33M	367.46M	372.48M	363.16M	360.90M	355.28M	357.52K
Diluted Earnings per Share	$0.00	-	-	-	-	-	-	-	-	-	-
Weighted Average Diluted Shares Outstanding	390.67M	379.15M	380.36M	379.43M	376.33M	367.46M	372.48M	363.16M	360.90M	355.28M	357.52K
Weighted Average Basic & Diluted Shares Outstanding	388.88M	384.55M	382.64M	382.62M	382.29M	380.69M	378.61M	378.01M	376.76M	376.37M	375.99M

This table details how cash moves in and out of LifeStance Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2019
Net Change in Cash & Equivalents	76	-30	-39	129	-7.86
Net Cash From Operating Activities	107	-17	53	9.42	17
Net Cash From Continuing Operating Activities	107	-17	53	9.42	17
Net Income / (Loss) Continuing Operations	-57	-186	-216	-307	5.67
Consolidated Net Income / (Loss)	-57	-186	-216	-307	5.67
Depreciation Expense	71	80	69	54	6.10
Amortization Expense	1.67	2.10	1.95	1.80	0.71
Non-Cash Adjustments To Reconcile Net Income	120	142	231	285	-0.18
Changes in Operating Assets and Liabilities, net	-28	-56	-34	-25	4.75
Net Cash From Investing Activities	-22	-60	-139	-194	-73
Net Cash From Continuing Investing Activities	-22	-60	-139	-194	-73
Purchase of Property, Plant & Equipment	-22	-41	-79	-94	-14
Acquisitions	0.00	-20	-60	-100	-59
Net Cash From Financing Activities	-9.95	47	47	314	48
Net Cash From Continuing Financing Activities	-9.95	47	47	314	48
Repayment of Debt	-291	-2.66	-197	-323	-2.45
Issuance of Debt	288	58	257	99	56
Other Financing Activities, net	-6.44	-7.67	-13	-12	-5.02
Cash Interest Paid	25	21	14	22	4.58
Cash Income Taxes Paid	0.06	0.08	2.24	1.09	0.25

This table details how cash moves in and out of LifeStance Health Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-20	52	16	38	-29	36	-37	11	-40	18	-6.35
Net Cash From Operating Activities	-3.09	62	23	44	-22	17	-25	-0.43	-7.89	36	5.73
Net Cash From Continuing Operating Activities	-3.09	62	23	44	-22	17	-25	-0.43	-7.89	36	5.73
Net Income / (Loss) Continuing Operations	0.71	-7.11	-5.96	-23	-21	-45	-62	-45	-34	-47	-38
Consolidated Net Income / (Loss)	0.71	-7.11	-5.96	-23	-21	-45	-62	-45	-34	-47	-38
Depreciation Expense	14	15	15	19	23	22	20	20	19	19	18
Amortization Expense	0.25	0.40	0.42	0.42	0.42	0.51	0.52	0.53	0.55	0.60	0.60
Non-Cash Adjustments To Reconcile Net Income	29	32	26	35	28	33	32	44	33	76	34
Changes in Operating Assets and Liabilities, net	-47	22	-12	14	-52	5.90	-16	-19	-26	-13	-8.74
Net Cash From Investing Activities	-7.17	-6.30	-5.05	-5.11	-5.10	-11	-9.80	-12	-28	-30	-20
Net Cash From Continuing Investing Activities	-7.17	-6.30	-5.05	-5.11	-5.10	-11	-9.80	-12	-28	-30	-20
Purchase of Property, Plant & Equipment	-7.17	-6.30	-5.05	-5.11	-5.10	-11	-9.80	-12	-7.73	-10	-15
Net Cash From Financing Activities	-9.98	-4.06	-2.03	-1.43	-2.43	31	-1.85	23	-4.89	13	8.19
Net Cash From Continuing Financing Activities	-9.98	-4.06	-2.03	-1.43	-2.43	31	-1.85	23	-4.89	13	8.19
Repayment of Debt	-1.81	-289	-0.73	-0.73	-0.73	-0.65	-0.65	-0.78	-0.59	-6.54	-0.08
Other Financing Activities, net	-8.16	-2.75	-1.29	-0.70	-1.70	-1.27	-1.20	-0.90	-4.30	-0.65	-1.20
Cash Interest Paid	4.38	5.97	6.40	6.36	6.27	5.62	5.59	4.77	5.06	4.85	4.59
Cash Income Taxes Paid	0.61	-0.00	0.21	0.10	-0.25	-0.34	0.10	0.33	-0.01	0.46	0.92

This table presents LifeStance Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	2,118	2,110	2,174	1,927	1,570
Total Current Assets	313	226	233	267	76
Cash & Equivalents	155	79	109	148	19
Accounts Receivable	132	125	101	76	44
Prepaid Expenses	26	22	24	42	14
Plant, Property, & Equipment, net	166	188	194	152	59
Total Noncurrent Assets	1,640	1,696	1,746	1,508	1,434
Goodwill	1,293	1,293	1,273	1,205	1,099
Intangible Assets	191	221	263	300	333
Other Noncurrent Operating Assets	156	182	210	3.45	2.65
Total Liabilities & Shareholders' Equity	2,118	2,110	2,174	1,927	1,570
Total Liabilities	672	681	655	382	537
Total Current Liabilities	229	203	176	117	76
Short-Term Debt	0.00	8.17	16	14	11
Accounts Payable	7.24	7.05	12	14	7.69
Accrued Expenses	47	35	30	27	15
Current Employee Benefit Liabilities	117	102	76	60	38
Other Current Liabilities	57	50	42	1.97	4.96
Total Noncurrent Liabilities	443	478	479	265	461
Long-Term Debt	280	280	225	157	363
Noncurrent Deferred & Payable Income Tax Liabilities	14	16	39	54	81
Other Noncurrent Operating Liabilities	149	182	215	54	17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,446	1,429	1,519	1,545	998
Total Preferred & Common Equity	1,446	1,429	1,519	1,545	998
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,446	1,429	1,519	1,545	998
Common Stock	2,264	2,187	2,088	1,902	1,011
Retained Earnings	-818	-761	-573	-357	-13
Accumulated Other Comprehensive Income / (Loss)	0.93	2.30	3.27	0.00	-

This table presents LifeStance Health Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	2,105	2,108	2,119	2,106	2,175	2,171	2,159	1,980
Total Current Assets	305	287	278	244	264	238	213	253
Cash & Equivalents	134	103	87	49	43	80	68	90
Accounts Receivable	140	158	167	176	150	122	118	113
Prepaid Expenses	30	26	24	19	72	36	26	49
Plant, Property, & Equipment, net	164	170	176	182	190	193	194	193
Total Noncurrent Assets	1,636	1,651	1,666	1,680	1,721	1,740	1,753	1,534
Goodwill	1,293	1,293	1,293	1,293	1,293	1,294	1,294	1,250
Intangible Assets	187	195	200	209	234	244	254	272
Other Noncurrent Operating Assets	156	162	172	178	194	203	205	11
Total Liabilities & Shareholders' Equity	2,105	2,108	2,119	2,106	2,175	2,171	2,159	1,980
Total Liabilities	648	671	689	677	720	676	653	448
Total Current Liabilities	207	218	228	207	241	181	181	112
Accounts Payable	7.42	7.28	9.97	12	10	8.04	7.71	7.95
Accrued Expenses	43	43	38	37	91	34	32	29
Current Employee Benefit Liabilities	100	112	123	100	84	81	84	62
Other Current Liabilities	57	53	53	53	47	47	44	2.63
Total Noncurrent Liabilities	440	453	462	470	479	495	472	336
Long-Term Debt	276	279	279	280	248	249	225	212
Noncurrent Deferred & Payable Income Tax Liabilities	14	15	16	16	38	38	38	55
Other Noncurrent Operating Liabilities	150	159	166	174	192	208	210	68
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,457	1,437	1,430	1,429	1,455	1,495	1,505	1,532
Total Preferred & Common Equity	1,457	1,437	1,430	1,429	1,455	1,495	1,505	1,532
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,457	1,437	1,430	1,429	1,455	1,495	1,505	1,532
Common Stock	2,274	2,247	2,233	2,208	2,167	2,145	2,112	2,054
Retained Earnings	-818	-811	-805	-782	-716	-654	-609	-526
Accumulated Other Comprehensive Income / (Loss)	0.61	0.77	2.64	2.89	4.38	4.15	2.00	3.19

This table displays calculated financial ratios and metrics derived from LifeStance Health Group's official financial filings.

Metric	2024	2023	2022	2021	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2019
Growth Metrics	-	-	-	-	-
Revenue Growth	18.50%	22.82%	28.77%	0.00%	0.00%
EBITDA Growth	140.40%	27.41%	40.55%	0.00%	0.00%
EBIT Growth	83.23%	12.89%	27.67%	0.00%	0.00%
NOPAT Growth	83.29%	10.01%	26.60%	0.00%	0.00%
Net Income Growth	69.16%	13.59%	29.83%	0.00%	0.00%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	735.28%	-131.98%	460.39%	0.00%	0.00%
Free Cash Flow Firm Growth	137.47%	47.79%	0.00%	0.00%	0.00%
Invested Capital Growth	-4.09%	-0.76%	5.26%	0.00%	0.00%
Revenue Q/Q Growth	3.72%	5.10%	4.80%	0.00%	0.00%
EBITDA Q/Q Growth	161.46%	15.60%	34.13%	0.00%	0.00%
EBIT Q/Q Growth	51.73%	7.84%	24.63%	0.00%	0.00%
NOPAT Q/Q Growth	51.32%	6.77%	24.38%	0.00%	0.00%
Net Income Q/Q Growth	39.72%	0.90%	23.01%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	73.73%	-854.09%	11.12%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	442.27%	18.86%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-2.76%	-1.87%	-0.78%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	3.32%	-9.74%	-16.48%	-35.69%	9.45%
Operating Margin	-2.53%	-17.92%	-24.45%	-42.90%	7.17%
EBIT Margin	-2.48%	-17.56%	-24.76%	-44.07%	6.25%
Profit (Net Income) Margin	-4.59%	-17.64%	-25.08%	-46.02%	2.67%
Tax Burden Percent	99.70%	90.16%	92.62%	92.22%	71.99%
Interest Burden Percent	185.38%	111.45%	109.36%	113.23%	59.28%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	28.01%
Return on Invested Capital (ROIC)	-1.38%	-8.05%	-9.14%	-12.78%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-22.47%	-39.55%	-96.97%	-466.84%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-2.62%	-4.59%	-4.93%	-7.10%	0.00%
Return on Equity (ROE)	-4.00%	-12.64%	-14.07%	-19.88%	0.00%
Cash Return on Invested Capital (CROIC)	2.80%	-7.29%	-14.27%	0.00%	0.00%
Operating Return on Assets (OROA)	-1.47%	-8.65%	-10.38%	-16.83%	0.00%
Return on Assets (ROA)	-2.72%	-8.70%	-10.51%	-17.57%	0.00%
Return on Common Equity (ROCE)	-4.00%	-12.64%	-14.07%	-19.61%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-3.97%	-13.04%	-14.19%	-19.88%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-132	-147	-200	11
NOPAT Margin	-1.77%	-12.54%	-17.12%	-30.03%	5.16%
Net Nonoperating Expense Percent (NNEP)	21.09%	31.51%	87.83%	454.06%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-1.28%	-7.71%	-8.36%	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	29.02%	38.91%	43.98%	134.79%	89.96%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	102.53%	117.92%	124.45%	142.90%	92.83%
Earnings before Interest and Taxes (EBIT)	-31	-185	-213	-294	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	42	-103	-142	-238	20
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	1.95	2.07	1.22	2.31	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	88.76	0.00
Price to Revenue (P/Rev)	2.25	2.81	2.16	5.34	3.39
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.87	1.94	1.21	2.29	0.00
Enterprise Value to Revenue (EV/Rev)	2.35	3.01	2.31	5.37	0.00
Enterprise Value to EBITDA (EV/EBITDA)	70.91	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	27.46	0.00	37.69	380.62	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	65.56	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.19	0.20	0.16	0.11	0.00
Long-Term Debt to Equity	0.19	0.20	0.15	0.10	0.00
Financial Leverage	0.12	0.12	0.05	0.02	0.00
Leverage Ratio	1.47	1.45	1.34	1.36	0.00
Compound Leverage Factor	2.73	1.62	1.46	1.54	0.00
Debt to Total Capital	16.21%	16.80%	13.69%	9.99%	0.00%
Short-Term Debt to Total Capital	0.00%	0.48%	0.90%	0.82%	0.00%
Long-Term Debt to Total Capital	16.21%	16.32%	12.79%	9.17%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	83.79%	83.20%	86.31%	90.01%	0.00%
Debt to EBITDA	6.74	-2.81	-1.70	-0.72	0.00
Net Debt to EBITDA	3.01	-2.04	-0.93	-0.10	0.00
Long-Term Debt to EBITDA	6.74	-2.73	-1.59	-0.66	0.00
Debt to NOPAT	-12.64	-2.18	-1.64	-0.86	0.00
Net Debt to NOPAT	-5.66	-1.58	-0.90	-0.12	0.00
Long-Term Debt to NOPAT	-12.64	-2.12	-1.53	-0.79	0.00
Altman Z-Score	2.57	2.33	1.44	5.27	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	1.36%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	1.37	1.11	1.33	2.28	0.00
Quick Ratio	1.25	1.01	1.19	1.92	0.00
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	45	-120	-230	0.00	0.00
Operating Cash Flow to CapEx	497.36%	-41.67%	66.61%	9.97%	119.10%
Free Cash Flow to Firm to Interest Expense	1.69	-5.65	-11.52	0.00	0.00
Operating Cash Flow to Interest Expense	4.04	-0.80	2.65	0.24	3.15
Operating Cash Flow Less CapEx to Interest Expense	3.23	-2.71	-1.33	-2.19	0.51
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.59	0.49	0.42	0.38	0.00
Accounts Receivable Turnover	9.73	9.33	9.72	11.15	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	7.06	5.52	4.96	6.31	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	37.52	39.12	37.57	32.75	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	37.52	39.12	37.57	32.75	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	1,572	1,639	1,651	1,569	0.00
Invested Capital Turnover	0.78	0.64	0.53	0.43	0.00
Increase / (Decrease) in Invested Capital	-67	-12	83	0.00	0.00
Enterprise Value (EV)	2,945	3,174	1,990	3,585	0.00
Market Capitalization	2,820	2,964	1,857	3,562	720
Book Value per Share	$3.78	$3.77	$4.04	$4.13	$0.00
Tangible Book Value per Share	($0.10)	($0.23)	($0.05)	$0.11	$0.00
Total Capital	1,726	1,717	1,760	1,717	0.00
Total Debt	280	288	241	172	0.00
Total Long-Term Debt	280	280	225	157	0.00
Net Debt	125	210	132	24	0.00
Capital Expenditures (CapEx)	22	41	79	94	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-71	-48	-36	16	0.00
Debt-free Net Working Capital (DFNWC)	84	31	73	164	0.00
Net Working Capital (NWC)	84	23	57	150	0.00
Net Nonoperating Expense (NNE)	35	54	68	107	5.30
Net Nonoperating Obligations (NNO)	125	210	132	24	0.00
Total Depreciation and Amortization (D&A)	73	83	71	56	6.80
Debt-free, Cash-free Net Working Capital to Revenue	-5.67%	-4.53%	-4.13%	2.38%	0.00%
Debt-free Net Working Capital to Revenue	6.68%	2.94%	8.50%	24.55%	0.00%
Net Working Capital to Revenue	6.68%	2.17%	6.66%	22.44%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	379.15M	367.46K	355.28K	374.27M	0.00
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	379.15M	367.46K	376.37M	374.27M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	384.55M	380.69M	376.37M	327.52K	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-22	-132	-147	-200	11
Normalized NOPAT Margin	-1.77%	-12.54%	-17.12%	-30.03%	5.16%
Pre Tax Income Margin	-4.61%	-19.57%	-27.08%	-49.90%	3.71%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-1.17	-8.74	-10.68	-7.56	2.46
NOPAT to Interest Expense	-0.83	-6.24	-7.38	-5.15	2.03
EBIT Less CapEx to Interest Expense	-1.98	-10.64	-14.66	-9.99	-0.19
NOPAT Less CapEx to Interest Expense	-1.65	-8.15	-11.36	-7.58	-0.62
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from LifeStance Health Group's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.83%	15.99%	18.95%	20.32%	18.94%	22.34%	20.84%	23.89%	24.37%	20.72%	25.15%
EBITDA Growth	91.37%	255.03%	129.73%	108.28%	160.12%	65.40%	-168.07%	38.25%	72.63%	71.63%	82.49%
EBIT Growth	110.81%	101.59%	100.04%	64.18%	55.31%	32.48%	-90.68%	22.70%	49.38%	58.89%	69.76%
NOPAT Growth	109.56%	103.28%	100.06%	67.06%	50.81%	29.86%	-91.45%	19.94%	47.43%	59.55%	68.85%
Net Income Growth	103.36%	84.18%	90.33%	48.82%	38.39%	3.64%	-62.69%	33.83%	45.06%	58.00%	68.57%
EPS Growth	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	85.84%	271.04%	189.62%	10,252.07%	-176.78%	-53.24%	-542.50%	-105.54%	-338.51%	17.25%	140.33%
Free Cash Flow Firm Growth	8,801.85%	771.75%	193.04%	160.27%	99.05%	91.20%	69.09%	75.70%	95.24%	0.00%	88.25%
Invested Capital Growth	-3.89%	-4.09%	-3.22%	-2.88%	-0.66%	-0.76%	0.35%	1.67%	3.42%	5.26%	10.62%
Revenue Q/Q Growth	2.30%	4.08%	0.13%	3.96%	7.07%	6.74%	1.28%	2.77%	10.13%	5.42%	3.83%
EBITDA Q/Q Growth	0.11%	0.17%	600.54%	-72.76%	181.10%	80.79%	-95.03%	-97.83%	53.32%	-48.83%	55.08%
EBIT Q/Q Growth	208.27%	1,577.42%	100.18%	-13.26%	54.76%	54.78%	-54.56%	-41.32%	31.65%	-27.71%	37.34%
NOPAT Q/Q Growth	51.46%	2,153.19%	100.29%	4.92%	48.03%	56.60%	-53.59%	-42.00%	25.90%	-18.47%	35.77%
Net Income Q/Q Growth	109.97%	-19.39%	74.41%	-10.33%	53.08%	26.99%	-35.41%	-32.81%	26.61%	-23.26%	44.92%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-104.96%	174.25%	-48.43%	301.76%	-230.03%	166.24%	-5,742.17%	94.50%	-121.97%	526.84%	-26.85%
Free Cash Flow Firm Q/Q Growth	-2.79%	26.07%	45.20%	4,990.03%	92.50%	82.54%	5.94%	22.53%	30.86%	38.65%	26.06%
Invested Capital Q/Q Growth	1.76%	-2.76%	-0.63%	-2.26%	1.54%	-1.87%	-0.28%	-0.02%	1.44%	-0.78%	1.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	4.69%	4.79%	4.98%	0.71%	2.72%	-3.58%	-19.91%	-10.34%	-5.37%	-12.67%	-8.98%
Operating Margin	0.48%	0.33%	0.02%	-5.11%	-5.58%	-11.50%	-28.28%	-18.65%	-13.50%	-20.06%	-17.85%
EBIT Margin	0.48%	0.16%	0.01%	-5.38%	-4.94%	-11.68%	-27.57%	-18.07%	-13.14%	-21.17%	-17.47%
Profit (Net Income) Margin	0.21%	-2.19%	-1.90%	-7.45%	-7.02%	-16.02%	-23.42%	-17.52%	-13.56%	-20.34%	-17.40%
Tax Burden Percent	-48.23%	80.13%	110.68%	102.90%	101.75%	117.34%	78.99%	87.42%	89.45%	86.86%	89.69%
Interest Burden Percent	-91.70%	-1,706.92%	-17,361.29%	134.66%	139.80%	116.87%	107.56%	110.91%	115.34%	110.64%	111.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.27%	0.18%	0.01%	-2.50%	-2.58%	-5.17%	-11.93%	-7.54%	-5.21%	-7.50%	-6.47%
ROIC Less NNEP Spread (ROIC-NNEP)	0.05%	-4.51%	-3.04%	-8.95%	-7.21%	-18.25%	-17.42%	-15.39%	-13.63%	-26.04%	-29.69%
Return on Net Nonoperating Assets (RNNOA)	0.01%	-0.53%	-0.41%	-1.15%	-0.99%	-2.12%	-2.03%	-1.50%	-1.10%	-1.32%	-0.89%
Return on Equity (ROE)	0.27%	-0.35%	-0.41%	-3.65%	-3.58%	-7.28%	-13.96%	-9.04%	-6.32%	-8.82%	-7.36%
Cash Return on Invested Capital (CROIC)	3.40%	2.80%	0.50%	-2.99%	-6.55%	-7.29%	-8.86%	-8.71%	-10.99%	-14.27%	0.00%
Operating Return on Assets (OROA)	0.29%	0.09%	0.01%	-2.90%	-2.55%	-5.76%	-13.33%	-8.37%	-5.80%	-8.87%	-7.36%
Return on Assets (ROA)	0.13%	-1.29%	-1.07%	-4.02%	-3.63%	-7.90%	-11.33%	-8.12%	-5.99%	-8.53%	-7.33%
Return on Common Equity (ROCE)	0.27%	-0.35%	-0.41%	-3.65%	-3.58%	-7.28%	-13.96%	-9.04%	-6.32%	-8.82%	-7.36%
Return on Equity Simple (ROE_SIMPLE)	-2.45%	0.00%	-6.63%	-10.55%	-12.11%	0.00%	-12.92%	-10.99%	-12.46%	0.00%	-18.28%
Net Operating Profit after Tax (NOPAT)	1.12	0.74	0.03	-11	-12	-23	-52	-34	-24	-32	-27
NOPAT Margin	0.34%	0.23%	0.01%	-3.57%	-3.91%	-8.05%	-19.80%	-13.06%	-9.45%	-14.04%	-12.50%
Net Nonoperating Expense Percent (NNEP)	0.22%	4.69%	3.04%	6.44%	4.63%	13.08%	5.49%	7.85%	8.42%	18.54%	23.22%
Return On Investment Capital (ROIC_SIMPLE)	0.06%	0.04%	-	-	-	-1.32%	-	-	-	-1.83%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	28.36%	-165.55%	95.15%	99.15%	98.07%	-164.97%	120.82%	111.13%	105.95%	-159.59%	109.63%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	99.52%	99.67%	99.99%	105.11%	105.58%	111.50%	128.28%	118.65%	113.50%	120.06%	117.85%
Earnings before Interest and Taxes (EBIT)	1.60	0.52	0.03	-17	-15	-33	-72	-47	-33	-49	-38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	16	16	16	2.22	8.16	-10	-52	-27	-14	-29	-20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.76	1.95	1.86	1.31	1.64	2.07	1.78	2.30	1.86	1.22	1.63
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	269.60
Price to Revenue (P/Rev)	2.00	2.25	2.22	1.62	2.13	2.81	2.59	3.59	3.08	2.16	3.04
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.69	1.87	1.77	1.27	1.55	1.94	1.68	2.16	1.77	1.21	1.58
Enterprise Value to Revenue (EV/Rev)	2.11	2.35	2.37	1.79	2.34	3.01	2.80	3.77	3.26	2.31	3.20
Enterprise Value to EBITDA (EV/EBITDA)	55.18	70.91	179.85	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	21.45	27.46	46.28	151.76	0.00	0.00	1,255.75	108.62	71.32	37.69	55.21
Enterprise Value to Free Cash Flow (EV/FCFF)	48.69	65.56	344.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.19	0.19	0.20	0.20	0.20	0.20	0.18	0.17	0.16	0.16	0.15
Long-Term Debt to Equity	0.19	0.19	0.19	0.20	0.20	0.20	0.17	0.17	0.15	0.15	0.14
Financial Leverage	0.13	0.12	0.14	0.13	0.14	0.12	0.12	0.10	0.08	0.05	0.03
Leverage Ratio	1.46	1.47	1.48	1.47	1.45	1.45	1.39	1.37	1.35	1.34	1.27
Compound Leverage Factor	-1.34	-25.10	-257.11	1.98	2.03	1.70	1.50	1.52	1.56	1.48	1.41
Debt to Total Capital	15.94%	16.21%	16.38%	16.53%	16.59%	16.80%	15.03%	14.78%	13.65%	13.69%	12.70%
Short-Term Debt to Total Capital	0.00%	0.00%	0.15%	0.22%	0.26%	0.48%	0.52%	0.60%	0.76%	0.90%	0.62%
Long-Term Debt to Total Capital	15.94%	16.21%	16.24%	16.31%	16.33%	16.32%	14.50%	14.18%	12.89%	12.79%	12.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.06%	83.79%	83.62%	83.47%	83.41%	83.20%	84.97%	85.22%	86.35%	86.31%	87.30%
Debt to EBITDA	5.64	6.74	17.72	-5.44	-3.51	-2.81	-2.11	-2.91	-2.25	-1.70	-1.04
Net Debt to EBITDA	2.90	3.01	11.26	-3.77	-2.90	-2.04	-1.76	-2.02	-1.61	-0.93	-0.62
Long-Term Debt to EBITDA	5.64	6.74	17.57	-5.37	-3.45	-2.73	-2.04	-2.79	-2.13	-1.59	-0.99
Debt to NOPAT	-29.82	-12.64	-6.19	-2.90	-2.36	-2.18	-1.81	-2.21	-1.90	-1.64	-1.15
Net Debt to NOPAT	-15.32	-5.66	-3.94	-2.01	-1.95	-1.58	-1.51	-1.53	-1.35	-0.90	-0.68
Long-Term Debt to NOPAT	-29.82	-12.64	-6.14	-2.87	-2.33	-2.12	-1.75	-2.12	-1.79	-1.53	-1.09
Altman Z-Score	2.50	2.62	2.47	1.65	2.08	2.57	2.07	3.03	2.56	1.69	3.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.47	1.37	1.32	1.22	1.18	1.11	1.10	1.32	1.17	1.33	2.25
Quick Ratio	1.32	1.25	1.20	1.12	1.09	1.01	0.80	1.11	1.03	1.19	1.81
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	66	68	54	37	-0.76	-10	-58	-61	-79	-115	-187
Operating Cash Flow to CapEx	-43.14%	988.99%	449.85%	862.23%	-427.86%	147.14%	-258.83%	-3.75%	-102.08%	345.90%	37.96%
Free Cash Flow to Firm to Interest Expense	21.45	7.22	9.94	6.36	-0.13	-1.82	-10.55	-12.00	-15.58	-22.21	-44.64
Operating Cash Flow to Interest Expense	-1.01	6.63	4.20	7.57	-3.70	3.04	-4.63	-0.08	-1.55	6.95	1.37
Operating Cash Flow Less CapEx to Interest Expense	-3.34	5.96	3.26	6.69	-4.56	0.97	-6.42	-2.35	-3.07	4.94	-2.24
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.61	0.59	0.56	0.54	0.52	0.49	0.48	0.46	0.44	0.42	0.42
Accounts Receivable Turnover	8.12	9.73	7.83	8.00	7.50	9.33	7.64	8.66	8.52	9.72	8.95
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	7.42	7.06	6.70	6.27	5.87	5.52	5.24	5.00	4.99	4.96	5.32
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	44.98	37.52	46.59	45.62	48.67	39.12	47.79	42.16	42.84	37.57	40.80
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	44.98	37.52	46.59	45.62	48.67	39.12	47.79	42.16	42.84	37.57	40.80
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,599	1,572	1,616	1,626	1,664	1,639	1,670	1,675	1,675	1,651	1,664
Invested Capital Turnover	0.79	0.78	0.73	0.70	0.66	0.64	0.60	0.58	0.55	0.53	0.52
Increase / (Decrease) in Invested Capital	-65	-67	-54	-48	-11	-12	5.75	28	55	83	160
Enterprise Value (EV)	2,703	2,945	2,857	2,073	2,584	3,174	2,812	3,620	2,966	1,990	2,623
Market Capitalization	2,561	2,820	2,678	1,877	2,349	2,964	2,597	3,440	2,796	1,857	2,490
Book Value per Share	$3.79	$3.78	$3.76	$3.74	$3.75	$3.77	$3.85	$3.97	$4.00	$4.04	$4.07
Tangible Book Value per Share	($0.06)	($0.10)	($0.13)	($0.17)	($0.19)	($0.23)	($0.19)	($0.11)	($0.11)	($0.05)	$0.02
Total Capital	1,733	1,726	1,719	1,713	1,713	1,717	1,712	1,754	1,743	1,760	1,754
Total Debt	276	280	282	283	284	288	257	259	238	241	223
Total Long-Term Debt	276	280	279	279	280	280	248	249	225	225	212
Net Debt	142	125	179	196	235	210	215	180	170	132	133
Capital Expenditures (CapEx)	7.17	6.30	5.05	5.11	5.10	11	9.80	12	7.73	10	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-37	-71	-31	-33	-8.34	-48	-10	-12	-24	-36	61
Debt-free Net Working Capital (DFNWC)	97	84	72	54	41	31	32	68	45	73	151
Net Working Capital (NWC)	97	84	70	50	37	23	23	57	31	57	140
Net Nonoperating Expense (NNE)	0.41	7.85	5.99	12	9.36	22	9.53	12	10	14	11
Net Nonoperating Obligations (NNO)	142	125	179	196	235	210	215	180	170	132	133
Total Depreciation and Amortization (D&A)	14	15	16	19	23	23	20	20	20	19	18
Debt-free, Cash-free Net Working Capital to Revenue	-2.89%	-5.67%	-2.54%	-2.86%	-0.76%	-4.53%	-1.02%	-1.26%	-2.60%	-4.13%	7.41%
Debt-free Net Working Capital to Revenue	7.58%	6.68%	5.97%	4.66%	3.73%	2.94%	3.22%	7.04%	4.91%	8.50%	18.43%
Net Working Capital to Revenue	7.58%	6.68%	5.76%	4.33%	3.32%	2.17%	2.33%	5.95%	3.45%	6.66%	17.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	383.27M	379.15M	380.36M	379.43M	376.33M	367.46M	372.48K	363.16K	360.90K	355.28M	357.52K
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	390.67M	379.15M	380.36M	379.43M	376.33M	367.46M	372.48K	363.16K	360.90K	355.28M	375.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	388.88M	384.55M	382.64M	382.62M	382.29M	380.69M	378.61M	378.01M	376.76M	376.37M	375.99M
Normalized Net Operating Profit after Tax (NOPAT)	1.12	0.74	0.03	-11	-12	-23	-52	-34	-24	-32	-27
Normalized NOPAT Margin	0.34%	0.23%	0.01%	-3.57%	-3.91%	-8.05%	-19.80%	-13.06%	-9.45%	-14.04%	-12.50%
Pre Tax Income Margin	-0.44%	-2.73%	-1.72%	-7.24%	-6.90%	-13.65%	-29.66%	-20.04%	-15.15%	-23.42%	-19.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.52	0.06	0.01	-2.88	-2.51	-5.93	-13.24	-9.16	-6.52	-9.40	-9.08
NOPAT to Interest Expense	0.37	0.08	0.01	-1.92	-1.99	-4.08	-9.50	-6.62	-4.69	-6.24	-6.49
EBIT Less CapEx to Interest Expense	-1.81	-0.62	-0.93	-3.76	-3.38	-7.99	-15.02	-11.42	-8.04	-11.41	-12.68
NOPAT Less CapEx to Interest Expense	-1.97	-0.59	-0.93	-2.79	-2.85	-6.15	-11.29	-8.88	-6.20	-8.25	-10.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About LifeStance Health Group's Financials

When does LifeStance Health Group's fiscal year end?

According to the most recent income statement we have on file, LifeStance Health Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has LifeStance Health Group's net income changed over the last 4 years?

Over the last 4 years, LifeStance Health Group's net income changed from $5.67 million in 2019 to -$57.44 million in 2024, a change of -1,113.3%. See LifeStance Health Group's forecast for analyst expectations on what’s next for the company.

What is LifeStance Health Group's operating income?

LifeStance Health Group's total operating income in 2024 was -$31.61 million, based on the following breakdown:

Total Gross Profit: $1.25 billion
Total Operating Expenses: $1.28 billion

How has LifeStance Health Group revenue changed over the last 4 years?

Over the last 4 years, LifeStance Health Group's total revenue changed from $212.52 million in 2019 to $1.25 billion in 2024, a change of 488.6%.

How much debt does LifeStance Health Group have?

LifeStance Health Group's total liabilities were at $672.01 million at the end of 2024, a 1.3% decrease from 2023, and a 25.2% increase since 2020.

How much cash does LifeStance Health Group have?

In the past 4 years, LifeStance Health Group's cash and equivalents has ranged from $18.83 million in 2020 to $154.57 million in 2024, and is currently $154.57 million as of their latest financial filing in 2024.

How has LifeStance Health Group's book value per share changed over the last 4 years?

Over the last 4 years, LifeStance Health Group's book value per share changed from 0.00 in 2019 to 3.78 in 2024, a change of 378.0%.

Related Companies

This page (NASDAQ:LFST) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeStance Health Group (LFST) Financials

Frequently Asked Questions About LifeStance Health Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeStance Health Group (LFST) Financials

Annual Income Statements for LifeStance Health Group

Quarterly Income Statements for LifeStance Health Group

Annual Cash Flow Statements for LifeStance Health Group

Quarterly Cash Flow Statements for LifeStance Health Group

Annual Balance Sheets for LifeStance Health Group

Quarterly Balance Sheets for LifeStance Health Group

Annual Metrics And Ratios for LifeStance Health Group

Quarterly Metrics And Ratios for LifeStance Health Group

Frequently Asked Questions About LifeStance Health Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools